Home / Transcripts / AVITA Medical, Inc. (RCEL) · November 5, 2026

AVITA Medical, Inc. (RCEL) Earnings Call Transcript

November 5, 2026

NASDAQ US Health Care Biotechnology earnings 36 min

Earnings Call Speaker Segments

Ben Atkins executive
#1

Thanks, operator. I'd like to welcome everyone to AVITA Medical's earnings call for the third quarter of 2026. With me today are Cary Vance, our President and Chief Executive Officer, and David O'Toole, our Chief Financial Officer. You can find today's earnings release and presentation in the Investor Relations section of our website, www.avitamedical.com. Before we get started, I want to remind you that forward-looking statements are included in this call, within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not promises or guarantees, and they carry known and unknown risks and uncertainties that might make actual results differ materially from any expectations expressed or implied by those forward-looking statements. For full descriptions of the risk factors, please review our most recent filings with the SEC. All forward-looking statements made on this call reflect management's expectations as of today. I'll now hand the call over to Cary.

Cary Vance executive
#2

Good afternoon in the U.S., and good morning to those of you in Australia. We're grateful, as always, that you've taken the time to be with us for this quarterly update call. Before I get into the quarter, I'd like to recognize the clinicians who are treating patients suffering from severe burns in the aftermath of the terrible fire at the Wainwright Military Base in Alberta, Canada. We acted swiftly once they reached out to us. Roughly three dozen RECELL units were donated to burn centers in Calgary and Edmonton, and we dispatched AVITA staff to provide training and support to the clinical teams. The first patient was treated with RECELL within a matter of days. Severe burn injuries can strike with no warning at all. Being able to respond requires preparation, access to treatment, and people who are ready to take action. I'd like to express appreciation to our team, to the clinicians and the burn community in Canada, and to the American Burn Association for bringing us together. RECELL is not commercially available in Canada, and we are thankful to Health Canada for moving swiftly to enable access. This effort reminds us why we do this work: helping people recover from severe wounds and get back to their lives. Now let me discuss our third quarter performance. Revenue came in at $26.1 million, a 53% increase year-over-year and 20% higher than the second quarter. RECELL drove that growth, with rising adoption of Cohealyx providing support. We'll go into more detail on our product dynamics shortly. Meanwhile, our cash usage dropped to roughly $600,000, down from $3.2 million in Q2. Revenue is climbing, and at the same time we're keeping a tight grip on costs and cash. That mix keeps strengthening the company's financial position. Given how we've performed, we're lifting our full-year revenue guidance for a second quarter in a row. For the entire year, we now anticipate $92 million to $94 million in revenue, up from the $86 million-$89 million range we gave before. We're also still on schedule to reach cash flow breakeven during Q4. David will go into the financial results and our liquidity in greater depth. Before that, I'd like to frame where we stand. Twelve months back, our goals were to get RECELL utilization on steady footing, re-engage our core accounts, and sharpen our operations. During Q1, we started seeing those steps produce steadier demand; by Q2, that demand fueled additional expansion and gave us confidence to lift guidance and set our cash flow breakeven target. Q3 carries that momentum forward; we keep expanding within our accounts. Hospitals are purchasing more RECELL, Cohealyx is reaching more customers, and revenue growth is converting into reduced cash use. Our commercial strategy stays focused. We aim at high-volume burn and Level I trauma centers where clinicians handle burns, traumatic injuries, and complex surgical wounds. We estimate this focused U.S. We estimate the addressable market is roughly $1.3 billion each year. Our job is to expand inside that market by reaching more physicians, enabling more eligible procedures, and driving wider use of our portfolio at each account. I'll begin with RECELL. U.S. RECELL revenue came in at $22.4 million, about 20% higher than Q2. U.S. RECELL volume climbed to 3,196 units, up roughly 21% sequentially. That follows a gain of more than 11% in Q2 over Q1. The increase reflects both higher procedure volumes and more ordering activity across our accounts. With RECELL GO and RECELL GO mini, clinicians can choose how to treat wounds of different sizes. The mini version brings the platform to smaller wounds, while RECELL GO is used for larger areas. This matters a lot, since a hospital's chance to help covers many kinds of patients, wound dimensions, and surgical groups. Our commercial and clinical staff work alongside physicians to identify appropriate cases, provide training, and promote steady adoption. Once doctors gain familiarity, they can decide how RECELL suits their own practice. The clinical proof supporting this work continues to grow too. In October, the Journal of Plastic, Reconstructive & Aesthetic Surgery ran a systematic review looking at 99 studies from 13 countries, covering over twenty years of experience with skin cell suspension autografting — which is essentially RECELL. All six comparative studies looking at how much donor skin is needed showed decreases when our technology was used, and the 18 studies that examined healing found results that were favorable or on par. Designs and quality varied among these studies, but collectively they capture extensive clinical experience spanning burns and other kinds of wounds. Less donor skin required is significant for clinicians. Harvesting donor tissue leaves behind a second wound that must then heal. Lightening that load can substantially affect how a patient recovers. Burn care is where RECELL built its clinical base, and it continues to be a meaningful growth driver. We also see opportunity in trauma and surgical repair, since physicians there encounter many of the same difficulties when it comes to closing wounds and achieving healing. As we mentioned last quarter, a new category 1 CPT code family covering skin cell suspension autografting is set to take effect on January 1, 2027. Under it, the existing structure will be simplified from eight codes down to four, determined by wound size and anatomic location. This week, the Centers for Medicare & Medicaid Services, or CMS, released its final rule and set national relative value units for physicians who perform procedures with RECELL under the Medicare Physician Fee Schedule. Starting in January, the new framework is going to take the place of the current pricing set by Medicare administrative contractors on a region-by-region basis, using RVUs published nationally instead. Clinicians have given us encouraging feedback regarding the simpler structure. Our team stands ready to help hospitals with coding information as well as practical guidance on implementation. Revenue from RECELL internationally came in at roughly $900,000, which was basically flat compared with Q2. We keep building experience with RECELL GO in markets where we hold regulatory authorization, including the first RECELL GO cases in Australia, the country where Dr. Wood originally developed RECELL. Although international is still a smaller contributor at present, our emphasis on training, clinical experience, and local relationships in key markets continues to support steadily broadening adoption over time. Let me now turn to Cohealyx. Revenue came in at $2.1 million, roughly 21% higher than Q2; we keep bringing on new customers as hospitals wrap up their value analysis committee reviews and start using Cohealyx. Those reviews matter a great deal for adoption. Hospitals need to weigh the clinical evidence, get a handle on the economics, and determine where a product fits into their treatment protocols. The interim Cohealyx I results help inform those discussions. The study reported a median time to graft readiness of about 11 days, and certain patients were ready inside the first week. We expect the complete six-month follow-up data set this month; it will add longer-term outcomes information to the early evidence we have already shared. Our priority continues to be assisting hospitals in completing their evaluations, and we're helping clinicians gain hands-on familiarity with the product. Turning to PermeaDerm, sales were roughly $600,000, basically unchanged from Q2. Given how early we are, order timing from one quarter to the next can swing the numbers. What we're working toward is a wider foundation of routine use. The PermeaDerm I data we shared in August provide stronger support for that effort. That randomized trial enrolled 40 patients at 11 U.S. burn centers. It pitted PermeaDerm against allograft — human skin transplanted from a deceased donor — for temporary wound coverage ahead of definitive split-thickness skin grafting. The study achieved its primary endpoint. When you look at product cost for each percentage point of total body surface area covered, PermeaDerm showed an economic advantage of 70% compared with allograft.

Cary Vance executive
#3

It also cut preparation time by roughly 96%, while graft take and wound healing results were comparable. About 94% of patients treated with PermeaDerm reached at least 95% graft take one week following autografting. Every patient in both groups had healed by eight weeks. These findings back a distinct role for PermeaDerm as a wound temporizer. Hospitals are able to keep it in storage at room temperature and apply it without tissue tracking, thawing, or meshing, all while keeping application time in the operating room comparable. Because it is transparent, clinicians can evaluate the wound without taking the covering off. Such features tackle practical difficulties in burn care, product availability, preparation time, and wound visibility. We have submitted the study for publication and are drawing on the findings in clinical education and hospital evaluations. The commercial task now is converting that evidence into adoption and repeat use. Throughout the portfolio, every product has a distinct purpose. PermeaDerm protects and stabilizes the wound. Cohealyx rebuilds the wound bed. RECELL restores the patient's skin. That provides us with multiple routes to address clinical needs within the same account, depending on the patient and the treatment plan. The American Burn Association's regional burn conferences offer an important forum where clinicians share emerging evidence and practical experience. At the four regional conferences this year, 26 presentations involved AVITA technologies. That exceeds the cumulative presence of several leading competitors. These presentations cover RECELL results across pediatric, geriatric, and other complicated burn patient groups, along with uses in facial and hand reconstruction and limb salvage. Four of these presentations feature treatment approaches that rely on two or more AVITA products, while additional ones offer clinical data for Cohealyx and PermeaDerm. With three regional conferences already completed and another coming next week, this high level of engagement highlights the expanding adoption of our portfolio and further widens the evidence base for broader clinical use. Before turning things over to David, I'd like to set our fourth quarter outlook in the context of this year's progress. Our full-year guidance points to Q4 revenue of roughly $24.9 million to $26.9 million. At the midpoint, that amounts to about 30% growth for the full year compared with 2025. Throughout the year, revenue climbed from $19.3 million in Q1 up to $21.7 million in Q2, and the range we've given for Q4 shows continued expansion on top of that level. The third quarter stood out, hitting $26.1 million, and summer's seasonal spike in high-burn admissions may have lent it some lift. Our guidance accounts for that Q3 fluctuation while still capturing the steady, improved sequential results we've posted through September. We're staying focused on closing out the year on a strong note and getting to cash flow breakeven. Our priorities haven't changed: drive greater RECELL utilization, boost adoption of Cohealyx and PermeaDerm, and keep up commercial growth along with financial discipline. With that, I'll turn things over to David.

David O'Toole executive
#4

Thank you, Cary. Good afternoon — and for those of you in Australia, good morning. The results we posted for the third quarter show just how much our steady top-line expansion is lifting the company's overall financial picture. Revenue rose 20% versus the second quarter, gross margin widened to 84%, and operating expenses stayed level. Taken together, those outcomes brought quarterly cash burn down to roughly $600,000, compared with $3.2 million in Q2. We also hit the revenue threshold needed to draw the remaining $10 million available under our credit facility with Perceptive Advisors LLC. Those funds came in this week, which bolsters our cash position as we move toward breakeven on cash flow. In the prepared remarks I'm about to give, I'll take you through the quarter's financial results, our liquidity, and our updated outlook. Beginning with revenue: third quarter revenue came in at $26.1 million, up 53% from $17.1 million a year earlier and 20% above this year's second quarter; that puts revenue for the first nine months of 2026 at roughly $67.1 million. As Cary described, RECELL drove the growth, with Cohealyx adding further contributions. Financially speaking, what matters is that we're carrying the added revenue on essentially the same operating cost base. Total operating expenses came to $24.6 million, level with the second quarter and 7% above the $23 million recorded in the prior year period. As anticipated, sales and marketing accounted for most of the year-over-year increase. That mainly reflected commissions and incentive compensation tied to stronger commercial performance. As I've noted before, sales compensation — commissions in particular — will rise as our commercial team brings in more revenue. We keep tight control over the remaining cost base so that top-line growth flows through to improved bottom line results. That's exactly what happened this quarter. Versus Q2 of this year, revenue grew by about $4.4 million while operating expense did not rise at all. We keep reviewing spending throughout the organization and looking for ways to gain efficiency while still funding our commercial priorities. Now to gross margin. Gross margin climbed to 84%, which is 270 basis points higher than the 81.3% posted in the prior year quarter and above the 81.9% recorded in the second quarter. Stronger RECELL revenue and gains in manufacturing efficiency drove that improvement. RECELL gross margin came in at 88.4%, and at present we expect it to stay in the 85% to 90% range over the next several quarters. As I've said before, Cohealyx and PermeaDerm generate lower gross margins than RECELL. As sales of those products grow, they will eventually weigh on our overall gross margin percentage; even so, we still see considerable room for RECELL revenue to expand, so any margin decline should not be large. Our other two products will add gross profit without demanding a proportional rise in operating expenses. That's still a key element of the portfolio's financial worth. In Q3, we produced roughly $21.9 million of gross profit—about $4.2 million more than in this year's second quarter. Net loss came down to $6.2 million, equal to a loss of $0.20 per share, versus $13.2 million, or $0.46 per share, during the same period a year ago. Within the current quarter's net loss was roughly $2.1 million of non-cash expense tied to warrant revaluation as our share price rose. That charge hurt both net loss and loss per share, but once again, it was non-cash. Now on to cash. During our Q2 call, we indicated that we anticipated cash use would fall further in Q3. We beat that expectation as we near cash generation. Net cash use dropped to about $600,000, down from $3.2 million in Q2 and $9.9 million in Q1; September closed with roughly $10.5 million in cash equivalents and marketable securities. The gain mirrors greater revenue, robust gross margins, and ongoing discipline in working capital management. It further shows the operating leverage we've been pursuing as the business expands. Moving to liquidity. The Perceptive credit facility we closed in January of this year made available a $10 million second tranche of debt, contingent on reaching at least $85 million in trailing 12-month net revenue. That revenue milestone has been met, and this week we drew the remaining $10 million available under the credit facility. These extra funds bolster our cash reserves as we progress toward cash flow breakeven and cash generation, and they will show up in our 2026 year-end balance sheet. Stronger operating performance and liquidity also enabled a significant change in our financial reporting. Management determined that the substantial doubt regarding our capacity to continue as a going concern had been removed. Our independent auditor agreed with that conclusion. As a result, our third quarter Form 10-Q no longer carries that substantial doubt qualification, and the outstanding debt is now categorized as a long-term liability. The Form 10-Q does contain disclosures about the plan management carried out to resolve the going concern conclusion identified in earlier quarters. These steps reflect the headway we've made in bettering both the operating performance and the financial position of the company. Shifting to our outlook, we are lifting full year 2026 revenue guidance to $92 million-$94 million, up from our prior range of $86 million-$89 million; this marks our second straight quarterly raise in revenue guidance. The new range implies roughly 28%-31% growth over 2025. At the midpoint, that would be $93 million in annual revenue. That compares with about $35 million in 2022 and works out to a compound annual growth rate of roughly 28% across four years, bringing us back to a more attractive growth trajectory relative to 2025. We also restate our target of reaching cash flow breakeven during Q4; we'll keep managing spending and collections carefully as we pursue that fourth-quarter objective. The financial trends behind that expectation are still evident. Revenue has increased every quarter in 2020. Gross margin has improved. We've kept operating expenses under control, and cash use has fallen considerably. To sum up, Q3 shows that greater revenue is converting into stronger financial results; we cut cash use substantially, improved our liquidity following the quarter's end, and lifted our revenue outlook for the full year. I'd like to thank our teams throughout AVITA for the efforts behind those results; with that, I'll return the call to Cary.

Cary Vance executive
#5

Appreciate that, David. The third quarter reflects the strides we're taking. RECELL saw stronger demand. Cohealyx continued its expansion. We bolstered the clinical evidence behind PermeaDerm, and we cut cash consumption considerably while revenue climbed. We've lifted our revenue guidance once more and stay committed to reaching cash flow breakeven in Q4. My thanks go to our team members for their efforts and to the clinicians who rely on us in caring for their patients. I'm also grateful to all of you for being here and for your ongoing backing. Operator, let's open it up for questions.

Frank Takkinen analyst
#6

Good. Really impressive quarter — congratulations. I'd like to start by asking about the outlook. I appreciate the comments about some summer seasonality possibly adding to Q3. Could you maybe give an approximate figure for that — how much do you think might have been sort of pulled forward into Q3? And I'm just trying to think through the low end versus the high end of Q4. You've done a really nice job of moving higher quarter-over-quarter, and obviously the midpoint is roughly flat quarter-over-quarter. I'm curious what that figure came to with the summer seasonality, and also any early thoughts on how we ought to view the quarter-over-quarter growth we posted this year as we move toward 2027. Thanks.

Cary Vance executive
#7

Thanks, Frank. Good to talk to you. I've given this a fair amount of thought. We've run some analytics. If I had to give a ballpark for Q3, I'd put it at roughly $1 million. It came from simply higher volume along with seasonality. I believe we need one more summer before we truly grasp some Q3 dynamics, but that's an approximation. If you consider 26.1 and then subtract another $1 million, bringing it to roughly 25.1, and spread that across Q2, then carry it forward to the level we expect in Q4 — from a trajectory perspective I'd call that fairly linear, a fairly robust growth curve, with a bit of added lift in Q3, as I mentioned, perhaps $1 million.

Frank Takkinen analyst
#8

All right, that helps. So while I understand you're not giving guidance for 2027, perhaps you could share some early thinking on how we ought to frame growth there, and then walk us through a few of the factors that are the main drivers underlying that 2027 growth.

Cary Vance executive
#9

Yes, I'd say the march goes on, Frank. I mean, there are no secrets here. We will keep marching and expanding at the pace I believe we've been expanding at, and I think several things will work in our favor: the reimbursement announcement taking effect on January 1st will work in our favor. A lot of those Cohealyx facts that have emerged from ABA will work in our favor, and we're now beginning to truly compete and win. We'll gain traction from PermeaDerm. We'll gain traction throughout the portfolio. I think how we grow, what the strategy is, how we execute — it's a straight line. I don't expect any surprises, other than that we hold onto our cost discipline, we keep some of the industry's best commercial talent, and we execute each day and each quarter.

Frank Takkinen analyst
#10

Okay, that's really useful. So perhaps we can fit in one final question for David. Excellent work on controlling OPEX. Could you add your thinking on operating expense for 2027, and in particular any seasonality we ought to anticipate in the first quarter of 2027? I recall that in the first quarter of 2026, some cash use anomalies took place. Any thoughts on 2027 would be much appreciated. Thanks.

David O'Toole executive
#11

Yes; looking at 2027, we don't anticipate headcount rising meaningfully, so we'll aim to hold our operating costs at the level where they stand today. As you mentioned, in the first quarter, we do see benefits resetting. We see incentive comp being paid; now, many of those expenses — at least the incentive comp — have already been accrued this year, correct? There's cash that will go out in the first quarter for many of those one-time payments. Regarding operating expenses, apart from commissions in sales and marketing as our revenue rises, there will be some variability there. At the same time, we'll be setting quotas, hopefully at a higher level, so those commissions will more or less remain consistent. I'd just repeat once more, we intend to keep operating expenses flat while growing revenue, so that we can generate cash next year.

Frank Takkinen analyst
#12

Understood. Appreciate it once more. What a strong quarter.

Cary Vance executive
#13

Thanks. I appreciate it.

Josh Jennings analyst
#14

Thanks. Good afternoon — it's really encouraging to see the business maintaining its momentum. I'd like to spend a moment on RECELL, which had an impressive quarter with 20% sequential growth. Cary, could you break down in a bit more detail what drove that growth — higher utilization within existing accounts, new physician adoption, and maybe new hospital activations in the trauma channel? What are you seeing in the utilization metrics that makes you confident this momentum can be sustained over the coming year?

Cary Vance executive
#15

Yes, I think we've seen consistency across the last few quarters. I think it holds. Our approach of expanding both in breadth and depth — bringing in additional physicians, introducing more procedures with those already on board, targeting smaller and more intricate wounds through education, an economic narrative and benefit, with RECELL GO mini and products suited to what they're aiming to accomplish — we anticipate remaining on the podium, not just at these regional conferences, but as we move into the early portion of next year, that will carry on with a great many podium presentations, peer pressure, education; all of it simply keeps going. Honestly, a lot of this has stayed quite steady and has been climbing slowly over time, so that single odd result stands out—and for now, my focus is simply on being upfront about what I can and can't explain. I'm reasonably sure that roughly $1 million out of the $26.1 stems from treating more patients, or from wounds being bigger, during that stretch. It's encouraging that we could support that greater number and bring in revenue from it. Yet nearly all of the Q3 expansion came from following our plan and executing consistently throughout every part of the portfolio — every wound category, newly added physicians, newly adopted procedures, the whole list — exactly as we had told you. We anticipate that pattern carrying on through the current quarter and on into next year.

Josh Jennings analyst
#16

Great. Perhaps a follow-up question. The commercial approach is developing well, with RECELL, Cohealyx, and PermeaDerm positioned together as one integrated wound care portfolio. I'd really like to hear a bit more specifically regarding cross-selling chances and applying several products to the same patient. I realize it's still early, and plenty of VAC approvals for Cohealyx and PermeaDerm are on the way in the future, but perhaps how you expect that to develop going into next year. Also, what's your thinking on how the product portfolio will evolve? Might there be some additions as we go through the coming 12 to 24 months? Many thanks for taking the questions.

Cary Vance executive
#17

Yes, that's a good question. Here's how we think about it. We consider it from the moment the patient arrives until the moment the patient departs. How can we make a difference there? How can we make a difference to its timing, its economics, its clinical outcome? And through our training, through our products. So at present, we essentially have three product lines. Based on the patient and the wound, we can have one, two, or three of those products in use; so, we anticipate that sort of pull-through; we've got an enormous amount of loyalty and trust established through RECELL. They're in cases, they're in the ORs daily, engaging in discussions in a genuinely consultative manner with physicians and clinicians. My expectation is that if another product line ever came along, would it have value? It would need to satisfy certain criteria that our others do, which essentially means attractive margins, an economic story, a speed to healing, an acceleration where it truly just fits with what we're doing, where it doesn't create a big distraction or disruption, and where it won't consume a whole lot of our people's selling time, where it simply can be folded in fairly seamlessly. So, that's roughly what we look for. It isn't something we require right now. I believe we need these two very new product lines, and even with RECELL GO and RECELL GO mini, even those are fairly new. But we keep searching for that because, as a company and as a commercial force, we aim to add value. If another product is part of that, we're always looking for it.

Operator operator
#18

Thank you. Ladies and gentlemen, I appreciate it. Right now, the queue shows no further questions. Everyone, thank you for joining us on today's call. That brings the program to a close. You may disconnect at this point. All of you, have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AVITA Medical, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AVITA Medical, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.